Important Information

This website is managed by Ultima Markets’ international entities, and it’s important to emphasise that they are not subject to regulation by the FCA in the UK. Therefore, you must understand that you will not have the FCA’s protection when investing through this website – for example:

  • You will not be guaranteed Negative Balance Protection
  • You will not be protected by FCA’s leverage restrictions
  • You will not have the right to settle disputes via the Financial Ombudsman Service (FOS)
  • You will not be protected by Financial Services Compensation Scheme (FSCS)
  • Any monies deposited will not be afforded the protection required under the FCA Client Assets Sourcebook. The level of protection for your funds will be determined by the regulations of the relevant local regulator.

Note: Ultima Markets is currently developing a dedicated website for UK clients and expects to onboard UK clients under FCA regulations in 2026.

If you would like to proceed and visit this website, you acknowledge and confirm the following:

  • 1.The website is owned by Ultima Markets’ international entities and not by Ultima Markets UK Ltd, which is regulated by the FCA.
  • 2.Ultima Markets Limited, or any of the Ultima Markets international entities, are neither based in the UK nor licensed by the FCA.
  • 3.You are accessing the website at your own initiative and have not been solicited by Ultima Markets Limited in any way.
  • 4.Investing through this website does not grant you the protections provided by the FCA.
  • 5.Should you choose to invest through this website or with any of the international Ultima Markets entities, you will be subject to the rules and regulations of the relevant international regulatory authorities, not the FCA.

Ultima Markets wants to make it clear that we are duly licensed and authorised to offer the services and financial derivative products listed on our website. Individuals accessing this website and registering a trading account do so entirely of their own volition and without prior solicitation.

By confirming your decision to proceed with entering the website, you hereby affirm that this decision was solely initiated by you, and no solicitation has been made by any Ultima Markets entity.

I confirm my intention to proceed and enter this website

Tag Archives: JNJ.US

娇生公司第四季业绩优于预估,惟新年前瞻保守 

娇生公司 (JNJ.US) 第四季度业绩优于分析师预期。 该公司公布的2023年第四季销售额为214亿美元,净收入达41.3 亿美元。每股盈余 (EPS) 为1.70 美元,而前年同期每股盈余是1.22 美元,当时净收入为32.3 亿美元。 不包括一次性项目,该公司最近一个季度的调整后每股盈余为 2.29 美元。    于分拆旗下消费者保健公司 Kenvue 后,娇生公司现在经两个业务部门运作:创新医学(由其制药部门组成)和医疗技术(医疗设备事业)。 本季创新医学收入成长 4.2%,达到 137 亿美元,而医疗科技销售额飙升 13.3%,达到 77 亿美元。  娇生公司在多种新疗法获得批准方面取得了进展,其中包括治疗膀胱癌的 Balversa 药物。 然而,该公司利润丰厚的 Stelara 药物最快将于 2024 年中期在欧洲面临日益激烈的竞争。 在投资者电话会议上,执行长华金·杜阿托 (Joaquin Duato) 表示,娇生正在寻求更多收购案,并愿意考虑「多种类型的交易」。  娇生公司 2024 年前瞻指引与 12 月预测一致。 该公司预计营运销售额将成长 5-6%,达到 882亿美元至890亿美元。 对于盈利,娇生预计调整后每股收益为 10.55-10.75 美元,较去年增长 6.4-8.4%。 该 EPS 指引与华尔街预期的 10.68 美元相同。  (娇生公司股价月线图)  免责声明  […]